New Two-Drug combo aims to keep aggressive uterine cancer at bay

NCT ID NCT06366347

Summary

This study is testing whether two drugs, abemaciclib and letrozole, can help control advanced or recurrent endometrial cancer after initial chemotherapy. The drugs are taken daily as maintenance therapy for up to two years to try to delay cancer progression. The trial will enroll 32 participants with specific tumor characteristics who have just completed standard treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute at Foxborough

    WITHDRAWN

    Foxborough, Massachusetts, 02035, United States

  • Dana-Farber Cancer Institute at Milford

    WITHDRAWN

    Milford, Massachusetts, 01757, United States

  • Dana-Farber Cancer Institute at South Shore Hospital

    RECRUITING

    Weymouth, Massachusetts, 02190, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.